These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 29570629)

  • 1. Constructing TC-1-GLUC-LMP2 Model Tumor Cells to Evaluate the Anti-Tumor Effects of LMP2-Related Vaccines.
    Sun L; Hao Y; Wang Z; Zeng Y
    Viruses; 2018 Mar; 10(4):. PubMed ID: 29570629
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunogenicity of a multiepitope plasmid DNA encoding T and B lymphocyte epitopes from latent membrane protein 2 (LMP2) of Epstein-Barr virus as a vaccine in mice.
    Li W; Chen Q; Lin Q; Lv Y; Feng J; Liu J; Xu W; Chen S; Zhu X; Zhang L
    Protein Pept Lett; 2013 Oct; 20(10):1136-43. PubMed ID: 23688153
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recognition of Epstein-Barr virus-associated gastric carcinoma cells by cytotoxic T lymphocytes induced in vitro with autologous lymphoblastoid cell line and LMP2-derived, HLA-A24-restricted 9-mer peptide.
    Okugawa K; Itoh T; Kawashima I; Takesako K; Mazda O; Nukaya I; Yano Y; Yamamoto Y; Yamagishi H; Ueda Y
    Oncol Rep; 2004 Oct; 12(4):725-31. PubMed ID: 15375491
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The generation and characterization of LMP2-specific CTLs for use as adoptive transfer from patients with relapsed EBV-positive Hodgkin disease.
    Bollard CM; Straathof KC; Huls MH; Leen A; Lacuesta K; Davis A; Gottschalk S; Brenner MK; Heslop HE; Rooney CM
    J Immunother; 2004; 27(4):317-27. PubMed ID: 15235393
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chimerically fused antigen rich of overlapped epitopes from latent membrane protein 2 (LMP2) of Epstein-Barr virus as a potential vaccine and diagnostic agent.
    Lin X; Chen S; Xue X; Lu L; Zhu S; Li W; Chen X; Zhong X; Jiang P; Sename TS; Zheng Y; Zhang L
    Cell Mol Immunol; 2016 Jul; 13(4):492-501. PubMed ID: 25864917
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapeutic LMP1 polyepitope vaccine for EBV-associated Hodgkin disease and nasopharyngeal carcinoma.
    Duraiswamy J; Sherritt M; Thomson S; Tellam J; Cooper L; Connolly G; Bharadwaj M; Khanna R
    Blood; 2003 Apr; 101(8):3150-6. PubMed ID: 12468425
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Specific cellular immune responses in mice immunized with DNA, adeno-associated virus and adenoviral vaccines of Epstein-Barr virus-LMP2 alone or in combination.
    Wang Z; Yang S; Zhou L; Du H; Mo W; Zeng Y
    Sci China Life Sci; 2011 Mar; 54(3):263-6. PubMed ID: 21416326
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analysis of Epstein-Barr viral DNA load, EBV-LMP2 specific cytotoxic T-lymphocytes and levels of CD4+CD25+ T cells in patients with nasopharyngeal carcinomas positive for IgA antibody to EBV viral capsid antigen.
    Mo WN; Tang AZ; Zhou L; Huang GW; Wang Z; Zeng Y
    Chin Med J (Engl); 2009 May; 122(10):1173-8. PubMed ID: 19493466
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Human Leukocyte Antigen (HLA) A*1101-Restricted Epstein-Barr Virus-Specific T-cell Receptor Gene Transfer to Target Nasopharyngeal Carcinoma.
    Zheng Y; Parsonage G; Zhuang X; Machado LR; James CH; Salman A; Searle PF; Hui EP; Chan AT; Lee SP
    Cancer Immunol Res; 2015 Oct; 3(10):1138-47. PubMed ID: 25711537
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic vaccine targeting Epstein-Barr virus latent protein, LMP1, suppresses LMP1-expressing tumor growth and metastasis in vivo.
    Lin MC; Lin YC; Chen ST; Young TH; Lou PJ
    BMC Cancer; 2017 Jan; 17(1):18. PubMed ID: 28056887
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Sequence analysis of the CTL epitopes in transmembrane region of latent membrane protein 2 of Epstein-Barr virus derived from nasopharyngeal carcinoma cells].
    Zhang NH; Zhang XS; Li J; Zhang RH; Gao YF; Zeng MS
    Ai Zheng; 2006 May; 25(5):566-9. PubMed ID: 16687075
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A novel latent membrane 2 transcript expressed in Epstein-Barr virus-positive NK- and T-cell lymphoproliferative disease encodes a target for cellular immunotherapy.
    Fox CP; Haigh TA; Taylor GS; Long HM; Lee SP; Shannon-Lowe C; O'Connor S; Bollard CM; Iqbal J; Chan WC; Rickinson AB; Bell AI; Rowe M
    Blood; 2010 Nov; 116(19):3695-704. PubMed ID: 20671118
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immune response of mice to a latency membrane protein 2 multiepitope antigen of Epstein-Barr virus applied as DNA vaccine and/or peptide vaccine.
    Li W; Chen Q; Chen H; Rao P; Xue X; Chen S; Zhu S; Zhang L
    Acta Virol; 2013; 57(1):51-8. PubMed ID: 23530824
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A recombinant modified vaccinia ankara vaccine encoding Epstein-Barr Virus (EBV) target antigens: a phase I trial in UK patients with EBV-positive cancer.
    Taylor GS; Jia H; Harrington K; Lee LW; Turner J; Ladell K; Price DA; Tanday M; Matthews J; Roberts C; Edwards C; McGuigan L; Hartley A; Wilson S; Hui EP; Chan AT; Rickinson AB; Steven NM
    Clin Cancer Res; 2014 Oct; 20(19):5009-22. PubMed ID: 25124688
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Dendritic cells transfected with recombinant adenovirus Ad5F35-LMP2 induces LMP2 specific immunity mediated by cytotoxic T lymphocytes in vitro].
    Mo WN; Zhou L; Wang Z; Tang AZ; Huang GW; Zeng Y
    Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2008 Aug; 22(4):254-6. PubMed ID: 19105335
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Selective amino acid substitutions of a subdominant Epstein-Barr virus LMP2-derived epitope increase HLA/peptide complex stability and immunogenicity: implications for immunotherapy of Epstein-Barr virus-associated malignancies.
    Micheletti F; Guerrini R; Formentin A; Canella A; Marastoni M; Bazzaro M; Tomatis R; Traniello S; Gavioli R
    Eur J Immunol; 1999 Aug; 29(8):2579-89. PubMed ID: 10458773
    [TBL] [Abstract][Full Text] [Related]  

  • 17. EBV-Directed T Cell Therapeutics for EBV-Associated Lymphomas.
    McLaughlin LP; Gottschalk S; Rooney CM; Bollard CM
    Methods Mol Biol; 2017; 1532():255-265. PubMed ID: 27873282
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel Epstein-Barr virus-like particles incorporating gH/gL-EBNA1 or gB-LMP2 induce high neutralizing antibody titers and EBV-specific T-cell responses in immunized mice.
    Perez EM; Foley J; Tison T; Silva R; Ogembo JG
    Oncotarget; 2017 Mar; 8(12):19255-19273. PubMed ID: 27926486
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [T cells recognizing EBV-epitopes arose in co-culture of peripheral blood mononuclear cells from EB-infected patients and dendritic cells loaded with LMP2-mixed peptides].
    Xing YP; Cen XN; Tong CR; Gu JY; Cai P; Tao XY; Jin X; Zhu P
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2008 Apr; 16(2):392-6. PubMed ID: 18426672
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression of HPV6b L1/EBV LMP2 multiepitope and immunogenicity in mice.
    Zhu S; Xue X; Liu J; Lu L; Zhao P; Wang J; Li W; Zhang L
    Acta Biochim Biophys Sin (Shanghai); 2010 Aug; 42(8):515-21. PubMed ID: 20705592
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.